Cleo Diagnostics Limited (COV), also known as Cleo, is developing a pioneering blood test aimed at revolutionising the early detection of ovarian cancer. Their innovative approach hinges on the patented CXCL10 biomarker, set to debut in their first product, AdnexaSureTM. This test promises to differentiate between benign and malignant growths with high accuracy, all while integrating seamlessly into existing diagnostic laboratory procedures globally. Cleo's initiative marks a significant step forward in enhancing diagnostic capabilities for ovarian cancer, potentially improving outcomes through earlier detection and intervention.